Deals & Capital Markets
BioMarin Bets $4.8 Billion on Amicus to Create Rare Disease Powerhouse
Dec 19, 2025
You're signed outSign in or to get full access.
BP
BIOMARIN PHARMACEUTICAL (BMRN)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering BIOMARIN PHARMACEUTICAL.